JY47
/ Hangzhou Jiuyuan Gene Engineering
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 17, 2026
Hangzhou Jiuyuan Genetic Biopharmaceutical…is pleased to announce that the investigational new drug (IND) application of the JY47 Injection…has obtained clinical trial approval by the…NMPA, with the indication being metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
(HKEXnews)
New trial • Metabolic Dysfunction-Associated Steatohepatitis
1 to 1
Of
1
Go to page
1